基于化疗的PD-1抑制剂在晚期肺腺癌治疗中效果及安全性分析  

Effect and safety of chemotherapy-based PD-1 inhibitors in the treatment of advanced lung adenocarcinoma

作　　者：李兴[1] 马丽娜[2] 程小珍[1] 崔荣花[1] 张曙波 LI Xing;MA Li'na;CHENG Xiaozhen;CUI Ronghua;ZHANG Shubo(Department of Oncology,Medicine,Affiliated Haikou Hospital of Xiangya Medical College,Central South University,Haikou 570208,China;不详)

机构地区：[1]中南大学湘雅医学院附属海口医院肿瘤化疗科,海口570208 [2]中南大学湘雅医学院附属海口医院神经内科,海口570208

出　　处：《实用医学杂志》2021年第3期365-368,共4页The Journal of Practical Medicine

基　　金：海南省卫生健康行业科研项目(编号:20A200355)。

摘　　要：目的探讨基于化疗的程序性细胞死亡蛋白-1(programmed cell death 1,PD-1)抑制剂在晚期肺腺癌治疗中效果及安全性。方法以我院2018年8月至2019年7月86例晚期肺腺癌患者为研究对象,随机分为对照组(46例)和观察组(40例)。两组均采用培美曲塞联合顺铂化疗,观察组加用PD-1抑制剂治疗,对比两组治疗效果、无进展生存期、血清肿瘤标志物水平、不良反应发生率。结果观察组客观缓解率明显高于对照组(P <0.05)。观察组PFS为9.3个月,对照组PFS中位数为5.3个月。治疗后3个月,观察组CYFRA21-1、CEA与对照组相比明显较低(P <0.05)。观察组疲乏、恶心、粒细胞减少、血小板降低发生率与对照组比较差异无统计学意义(P> 0.05);观察组皮疹、甲状腺功能减退发生率高于对照组,两组甲状腺功能异常发生率差异有统计学意义(P=0.041)。结论 PD-1抑制剂在晚期肺腺癌中疗效好且安全性较高。Objective To investigate the effect and safety analysis of PD-1 inhibitors in the treatment of advanced lung adenocarcinoma.Methods 86 patients with advanced lung adenocarcinoma from August 2018 to July 2019 in our hospital were selected as the research object,and were randomly divided into the control group(46 cases)and an the observation group(40 cases).The control group and observation group were given pemetrex Cypriot combined with cisplatin,while the observation group was additionally treated with PD 1 inhibitors.The serum tumor marker levels,treatment effects,and incidence of adverse reactions,survival time were compared between the two groups.Results The objective remission rate(ORR)of the observation group was significantly higher than that of the control group(P<0.05).The PFS in the observation group was 9.3 months,and the median PFS in the control group was 5.3 months.3 months after treatment,the CYFRA21-1,CEA level of the observation group compared with the control group was significantly lower(P<0.05).The incidence of fatigue,nausea,neutropenia,and thrombocytopenia in the observation group were not significantly different from those in the control group(P>0.05).The incidence of rash,hypothyroidism in the observation group was higher than that in the control group,and the difference in the incidence of abnormal energy was statistically significant(P=0.041).Conclusion PD-1 inhibitors are effective and safe in advanced lung adenocarcinoma.

关 键 词：PD-1抑制剂 晚期肺腺癌 客观缓解率 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]